Empagliform 5/1000 Mg 30 Tabs

Empagliform 5/1000 Mg 30 Tabs

Description:

Empagliform 5/1000 mg 30 tabs is a prescription oral antidiabetic medicine used to help control blood glucose levels in adults with type 2 diabetes mellitus. It combines two active ingredients, empagliflozin (an SGLT2 inhibitor) and metformin (a biguanide), to improve glycemic control when used together with a proper diet and regular exercise. Empagliform is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. It is not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.

Indications:

• Management of blood glucose levels in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.
• May be used as monotherapy (when metformin alone is not appropriate) or in combination with other antidiabetic medications (such as insulin, sulfonylureas, DPP-4 inhibitors, etc.) as prescribed by a physician.
• Reduction of the risk of cardiovascular death in adults with type 2 diabetes mellitus and known cardiovascular disease.
• Helps reduce elevated fasting and postprandial (after-meal) blood sugar levels and improve overall glycemic control.

Active Ingredients / Key Components:

• Empagliflozin – 5 mg per film-coated tablet (sodium-glucose cotransporter-2 (SGLT2) inhibitor).
• Metformin hydrochloride – 1000 mg per film-coated tablet (biguanide class oral antidiabetic).
• Other excipients: Film-coating and tablet core excipients (full excipient list is not available in the provided information).

Dosage & Administration / How to Use:

• Use only as prescribed by your physician. The dose and duration are individualized based on blood glucose control, kidney function, and concomitant medications.
• Typical regimen: One tablet taken once or twice daily as directed by the doctor. Do not exceed the prescribed dose.
• Tablets should generally be taken with meals to reduce gastrointestinal side effects associated with metformin (such as nausea and stomach upset), unless your doctor advises otherwise.
• Swallow the tablet whole with a glass of water. Do not crush, break, or chew the film-coated tablets.
• If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed dose.
• Regular monitoring of blood glucose, kidney function, and other laboratory parameters is recommended during treatment.
• Not recommended for children and adolescents under 18 years of age.
• Always follow your doctor’s instructions regarding diet, exercise, and concurrent use of other antidiabetic medicines.

Clinical Benefits:

• Provides dual mechanism of action: empagliflozin increases urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.
• Helps lower fasting and postprandial blood glucose levels, contributing to improved HbA1c control in type 2 diabetes.
• Supports weight management in many patients due to increased glucose loss in urine (caloric loss) associated with SGLT2 inhibition.
• Reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease when used as prescribed.
• May help reduce blood pressure modestly in some patients due to osmotic diuresis from increased urinary glucose and sodium excretion.
• Convenient fixed-dose combination improves treatment adherence by reducing the number of separate tablets needed.

Warnings & Contraindications:

• Contraindicated in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis (DKA).
• Do not use if you have severe kidney problems, significantly reduced kidney function, or are on dialysis. Kidney function should be assessed before starting and periodically during treatment.
• Not recommended during pregnancy or breast-feeding. If you become pregnant or plan to become pregnant, inform your doctor immediately.
• Contraindicated in patients with known hypersensitivity to empagliflozin, metformin, or any of the excipients.
• Metformin is associated with a rare but serious risk of lactic acidosis, particularly in patients with significant renal impairment, severe infection, dehydration, heart failure, liver impairment, or excessive alcohol intake.
• Use with caution in elderly patients, patients with cardiovascular disease, low blood pressure, or those taking diuretics, due to risk of volume depletion and hypotension.
• Empagliflozin may increase the risk of genital mycotic (fungal) infections and urinary tract infections; maintain good personal hygiene and report symptoms promptly.
• Consult your doctor before use if you have liver disease, heart failure, history of pancreatitis, recurrent urinary tract infections, or are taking other glucose-lowering medications (risk of hypoglycemia when combined with insulin or sulfonylureas).
• Avoid excessive alcohol intake while taking metformin-containing products due to increased risk of lactic acidosis.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision. Use only under the guidance of a qualified healthcare professional.
• Keep out of reach of children.

Side Effects:

• Common side effects: nausea, vomiting, diarrhea, abdominal discomfort, loss of appetite (mainly related to metformin); increased urination, thirst, and mild dehydration (related to empagliflozin); genital yeast infections (vulvovaginal candidiasis in women, balanitis in men); urinary tract infections.
• Less common side effects: dizziness or low blood pressure (especially in patients on diuretics or with low blood volume), increased blood lipids, rash or hypersensitivity reactions.
• Serious but rare side effects: lactic acidosis (symptoms include rapid breathing, severe weakness, muscle pain, stomach pain with nausea/vomiting, feeling very cold, dizziness, slow or irregular heartbeat); severe urinary tract infection or urosepsis; ketoacidosis in patients with type 2 diabetes (even with normal or moderately elevated blood glucose levels); severe allergic reactions (swelling of face, lips, tongue, or throat, difficulty breathing).
• Hypoglycemia (low blood sugar) is more likely when Empagliform is used together with insulin or insulin secretagogues (e.g., sulfonylureas). Symptoms include sweating, tremor, hunger, confusion, palpitations, and headache.
• If you experience signs of lactic acidosis, severe infection, severe abdominal pain, difficulty breathing, or symptoms of severe allergic reaction, stop taking the medicine and seek immediate medical attention.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription oral antidiabetic medicine.
• Form: Film-coated tablet.
• Strength per tablet: empagliflozin 5 mg + metformin hydrochloride 1000 mg.
• Pack size: 30 film-coated tablets per pack.
• Intended use: Adult patients with type 2 diabetes mellitus under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.